OncoCyte Corporation
OCX
$2.72
$0.072.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.14M | 1.49M | 115.00K | 104.00K | 176.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.14M | 1.49M | 115.00K | 104.00K | 176.00K |
| Cost of Revenue | 806.00K | 869.00K | 43.00K | 32.00K | 109.00K |
| Gross Profit | 1.33M | 617.00K | 72.00K | 72.00K | 67.00K |
| SG&A Expenses | 4.32M | 3.76M | 3.61M | 3.26M | 3.52M |
| Depreciation & Amortization | 7.00K | 22.00K | 22.00K | 22.00K | 22.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.98M | 6.91M | 6.49M | 5.77M | 5.96M |
| Operating Income | -5.84M | -5.42M | -6.38M | -5.66M | -5.79M |
| Income Before Tax | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M |
| EBIT | -5.84M | -5.42M | -6.38M | -5.66M | -5.79M |
| EBITDA | -5.35M | -4.86M | -6.04M | -5.34M | -5.45M |
| EPS Basic | -0.26 | -1.93 | -0.98 | -0.36 | -1.13 |
| Normalized Basic EPS | -0.14 | -0.19 | -0.29 | -0.27 | -0.43 |
| EPS Diluted | -0.26 | -1.93 | -0.98 | -0.36 | -1.13 |
| Normalized Diluted EPS | -0.14 | -0.19 | -0.29 | -0.27 | -0.43 |
| Average Basic Shares Outstanding | 25.69M | 17.38M | 13.71M | 12.87M | 8.26M |
| Average Diluted Shares Outstanding | 25.69M | 17.38M | 13.71M | 12.87M | 8.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |